NasdaqGS:EXELBiotechs
Assessing Exelixis (EXEL) Valuation After FDA Accepts Zanzalintinib NDA In Metastatic Colorectal Cancer
Exelixis (EXEL) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, supported by phase 3 overall survival data.
See our latest analysis for Exelixis.
The NDA news comes as Exelixis trades at US$42.59, with recent 1 month and year to date share price returns slightly negative. However, a 90 day share price return of 5.5% sits alongside a 1 year total shareholder...